Inhibitory protonové pumpy (IPP) jsou terapeutickou volbou u ezofagitidy a gastritidy. Recentní studie nepotvrzují benefit IPP chronického kašle, kojeneckého refluxu, astmatu či funkčních gastrointestinálních obtíží. Jsou popisovány nežádoucí účinky vyplývající z omezení diverzity mikrobiomu postižení imunitních funkcí toho plynoucích infekcí, fraktur alergických ...

Mucosal protective agents may improve healing of patients with endoscopic submucosal dissection-induced ulcers. The present study systematically evaluated published clinical trials to determine whether combined therapeutic use of mucosal protective agents and proton pump inhibitors can improve the outcome of patients with endoscopic submucosal dissection-induced ulcers compared to treatment wit...

CONTEXT Gastroesophageal reflux disease (GERD) is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Its pathophysiology, diagnosis and treatment have frequently been analyzed but it is interesting to review some aspects of the GERD refractory patients to the proton pump inhibitors treatment. The treatment encompasses behavioral meas...

The effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes were examined. Groups of female Sprague-Dawley rats were orally administered pantoprazole and other proton pump inhibitors, omeprazole and lansoprazole, at 5, 50, or 300 mg/kg/day for 7 days, followed by assays to detect changes in the levels of liver microsomal protein, cytochrome P450, cytochrome b5, NADPH ...